EP 31

Neuroendocrine Peptide Analogs

This episode explores the world of neuroendocrine peptides, the body's own signaling molecules that bridge the nervous system and endocrine functions. From the early days of insulin to the latest advancements in peptide engineering, we delve into the challenges and successes of using these molecules as drugs. With over 80 peptide drugs on the market, the field has seen massive growth in recent years, and we examine the key factors driving this progress.

neuroendocrine peptidespeptide engineeringinsulin analogsGLP-1 analogspolyagonists

play_arrowListen to episode

Key Concepts

Neuroendocrine Peptides

Neuroendocrine peptides are small, elegant signaling molecules that play a crucial role in the body's internal communication network.
They bridge the nervous system and endocrine functions, enabling the body to respond to various stimuli.

Peptide Engineering

Peptide engineering involves the design and creation of peptides with improved properties, such as increased stability and selectivity.
This is achieved through rational design and engineering, using techniques such as amino acid substitution and cyclization.

Insulin Analogs

Insulin analogs are engineered to have improved properties, such as faster or slower action.
Examples include Lispro, Aspart, and Glargine, which have been designed to improve glycemic control.

GLP-1 Analogs

GLP-1 analogs are used to treat diabetes and obesity, and have been engineered to have improved properties, such as increased half-life and selectivity.
Examples include Exenatide, Liraglutide, and Semaglutide, which have been shown to improve glycemic control and weight loss.

Polyagonists

Polyagonists are molecules that combine multiple hormone targets, enabling the treatment of complex diseases.
Examples include dual GLP-1/GIP agonists, which have been shown to improve glycemic control and weight loss.

Episode Summary

check_circleNeuroendocrine peptides are small, elegant signaling molecules that play a crucial role in the body's internal communication network.
check_circleThe first life-saving insulin shots marked the beginning of peptide therapies, but it wasn't until recently that the field has seen rapid growth.
check_circleThere are now over 80 peptide drugs on the market, with most approvals happening in the last 20 years.
check_circleThe success of peptide drugs is attributed to the cracking of major problems such as rapid degradation and clearance, poor oral bioavailability, and the blood-brain barrier.
check_circleEngineered analogs have been designed to be more stable, selective, and long-lasting, leading to significant advancements in the field.
check_circleExamples of successful peptide drugs include insulin analogs, somatostatin analogs, and GLP-1 analogs.
check_circleThe use of rational design and engineering has enabled the creation of peptides with improved properties, such as increased half-life and selectivity.
check_circleThe field is now moving towards the development of polyagonists, which combine multiple hormone targets, and hybrid molecules that combine peptides with other molecules.
check_circleChronic pain is a significant area of need, and peptide-based treatments are being explored as non-addictive options.
check_circleTechnology, including biotech advancements and computational power, is accelerating the development of peptide drugs.

Full Transcript

Discussion

Join the discussion — sign in to leave a comment.